Last reviewed · How we verify
Chronic graft-versus-host disease
Approved treatments
- Imbruvica · AbbVie
Imbruvica works by blocking the activity of a specific enzyme called Bruton's tyrosine kinase (BTK), which is involved in the growth and survival of cancer cells. - Imbruvica · Rabin Medical Center
- Jakafi · Incyte Corp
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Chronic graft-versus-host disease patent landscape — cliff calendar, originator estates, attackable patents
- Chronic graft-versus-host disease treatment landscape brief
- Chronic graft-versus-host disease treatment updates RSS
Frequently asked questions about Chronic graft-versus-host disease
What drugs treat Chronic graft-versus-host disease?
Tracked treatments include Imbruvica, Jakafi.
What is the treatment for Chronic graft-versus-host disease?
Standard treatment for Chronic graft-versus-host disease includes Imbruvica, Jakafi. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Chronic graft-versus-host disease patent cliff · Chronic graft-versus-host disease CI report
- Treatment: Imbruvica · AbbVie
- Treatment: Imbruvica · Rabin Medical Center
- Treatment: Jakafi · Incyte Corp
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing